We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clovis (CLVS) Q4 Earnings Miss, Revenues Beat, Stock Down
Read MoreHide Full Article
Clovis Oncology incurred loss of $1.02 per share for the fourth quarter of 2020, wider than the Zacks Consensus Estimate of a loss of 76 cents but narrower than the year-ago loss of $1.81 per share.
Net revenues, entirely from Clovis’ only marketed drug, Rubraca, were up almost 10.2% year over year to $43.3 million in the quarter, slightly beating the Zacks Consensus Estimate of $43.16 million.
Shares of Clovis were down almost 6.1% in pre-market trading, following the dismal earnings performance. The stock has plunged 32.7% in the past year compared with the industry’s decrease of 11.4%.
Quarter in Details
Sales of Rubraca, a PARP inhibitor, in the United States were $36.4 million, compared with $36.1 million in the fourth quarter of 2019. Ex-U.S. market sales were $6.9 million in the fourth quarter compared with $3.2 million in the year-ago quarter.
In the fourth quarter, research & development expenses decreased 21.8% year over year to $56.7 million, primarily due to lower spending on Rubraca clinical studies. Selling, general and administrative expenses declined 9.7% year over year to $40.8 million, driven by cost-saving initiatives and savings due to the COVID-19 situation globally.
Clovis ended the quarter with $240.2 million of cash equivalents and available-for-sale securities compared with $224.7 million as of Sep 30, 2020.
The company expects its cash resources, along with anticipated revenues and available financing sources, to be enough to support its operations in early 2023.
Full-Year Results
Clovis reported revenues of $164.5 million, up 12.4% year over year. The company’s incurred a loss of $4.38 per share in 2020, 41% narrower than the year-ago period.
Update on Rubraca
In December, Clovis announced that the phase III confirmatory study — ARIEL 4 — evaluating Rubraca met its primary endpoint of improved investigator-assessed progression-free survival. The study was a post-marketing commitment in the United States and Europe
The company has a collaboration with Bristol-Myers (BMY - Free Report) to develop Rubraca and pipeline candidate, lucitanib, in combination with the latter’s PD-L1 inhibitor, Opdivo, for several cancer indications. The phase III ATHENA study is evaluating Rubraca plus Opdivo as first-line maintenance treatment in advanced ovarian cancer. Top-line data is expected in the second half of 2021. Interim data from phase II part of LIO-1 study evaluating lucitanib in combination with Opdivo as potential treatment for gynecologic cancers is expected later this year at medical meetings.
A phase II LODESTAR study is evaluating Rubraca in patients with recurrent solid tumors associated with the deleterious homologous recombination repair or HRR gene mutations. Data from the study may be used to file a regulatory application by the end of 2021 or first-half 2022, seeking approval for Rubraca in HRR patients.
The company plans to initiate a phase I/II study in the first half of 2021 to evaluate its peptide-targeted radionuclide therapy and imaging agent candidate, FAP-2286, in multiple tumor types.
Clovis Oncology, Inc. Price, Consensus and EPS Surprise
Moderna’s earnings per share estimates have moved up from $9.45 to $14.74 for 2021 in the past 60 days. The stock has soared 757.3% in the past year.
Lexicon’s loss per share estimates narrowed from 66 cents to 17 cents for 2021 in the past 60 days. The company delivered an earnings surprise of 21.72%, on average, in the last four quarters. The stock has risen 170.8% in the past year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Clovis (CLVS) Q4 Earnings Miss, Revenues Beat, Stock Down
Clovis Oncology incurred loss of $1.02 per share for the fourth quarter of 2020, wider than the Zacks Consensus Estimate of a loss of 76 cents but narrower than the year-ago loss of $1.81 per share.
Net revenues, entirely from Clovis’ only marketed drug, Rubraca, were up almost 10.2% year over year to $43.3 million in the quarter, slightly beating the Zacks Consensus Estimate of $43.16 million.
Shares of Clovis were down almost 6.1% in pre-market trading, following the dismal earnings performance. The stock has plunged 32.7% in the past year compared with the industry’s decrease of 11.4%.
Quarter in Details
Sales of Rubraca, a PARP inhibitor, in the United States were $36.4 million, compared with $36.1 million in the fourth quarter of 2019. Ex-U.S. market sales were $6.9 million in the fourth quarter compared with $3.2 million in the year-ago quarter.
In the fourth quarter, research & development expenses decreased 21.8% year over year to $56.7 million, primarily due to lower spending on Rubraca clinical studies. Selling, general and administrative expenses declined 9.7% year over year to $40.8 million, driven by cost-saving initiatives and savings due to the COVID-19 situation globally.
Clovis ended the quarter with $240.2 million of cash equivalents and available-for-sale securities compared with $224.7 million as of Sep 30, 2020.
The company expects its cash resources, along with anticipated revenues and available financing sources, to be enough to support its operations in early 2023.
Full-Year Results
Clovis reported revenues of $164.5 million, up 12.4% year over year. The company’s incurred a loss of $4.38 per share in 2020, 41% narrower than the year-ago period.
Update on Rubraca
In December, Clovis announced that the phase III confirmatory study — ARIEL 4 — evaluating Rubraca met its primary endpoint of improved investigator-assessed progression-free survival. The study was a post-marketing commitment in the United States and Europe
The company has a collaboration with Bristol-Myers (BMY - Free Report) to develop Rubraca and pipeline candidate, lucitanib, in combination with the latter’s PD-L1 inhibitor, Opdivo, for several cancer indications. The phase III ATHENA study is evaluating Rubraca plus Opdivo as first-line maintenance treatment in advanced ovarian cancer. Top-line data is expected in the second half of 2021. Interim data from phase II part of LIO-1 study evaluating lucitanib in combination with Opdivo as potential treatment for gynecologic cancers is expected later this year at medical meetings.
A phase II LODESTAR study is evaluating Rubraca in patients with recurrent solid tumors associated with the deleterious homologous recombination repair or HRR gene mutations. Data from the study may be used to file a regulatory application by the end of 2021 or first-half 2022, seeking approval for Rubraca in HRR patients.
The company plans to initiate a phase I/II study in the first half of 2021 to evaluate its peptide-targeted radionuclide therapy and imaging agent candidate, FAP-2286, in multiple tumor types.
Clovis Oncology, Inc. Price, Consensus and EPS Surprise
Clovis Oncology, Inc. price-consensus-eps-surprise-chart | Clovis Oncology, Inc. Quote
Zacks Rank
Clovis currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the drug/biotech sector include Moderna, Inc. (MRNA - Free Report) and Lexicon Pharmaceuticals, Inc. (LXRX - Free Report) . While Moderna sports a Zacks Rank #1 (Strong Buy), Lexicon carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Moderna’s earnings per share estimates have moved up from $9.45 to $14.74 for 2021 in the past 60 days. The stock has soared 757.3% in the past year.
Lexicon’s loss per share estimates narrowed from 66 cents to 17 cents for 2021 in the past 60 days. The company delivered an earnings surprise of 21.72%, on average, in the last four quarters. The stock has risen 170.8% in the past year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>